Michael S. Kinch, Ph.D. is Dean of Sciences and Vice President for Innovation at Long Island University. Michael’s research experiences include the discovery and development of medicines to treat or prevent cancer and pandemic diseases. He also founded and leads the Center for Research Innovation in Biotechnology (CRIB), which analyzes trends in the science, business, medicine and law for experimental and approved therapeutics.
Dr. Kinch’s scientific background includes the development of medicines for cancer, immunological and infectious diseases. His current work is focused upon understanding the blend of science, medicine, business and law needed to support the development of new medicines. Prior to Long Island University, Michael was an Associate Vice Chancellor at Washington University in St Louis. He also led drug discovery at Yale University as Managing Director of the Yale Center for Molecular Discovery. Dr. Kinch had served as Vice President of Research & Development and Chief Scientific Officer at Functional Genetics, Inc. in Gaithersburg, MD, where his research included investigation of Ebola, Dengue fever, pandemic influenza and other emerging infectious diseases. Preceding that, Dr. Kinch led the Departments of Cancer Biology and In Vivo Biology at MedImmune, Inc. Prior to MedImmune, Dr. Kinch served as a tenured professor at Purdue University. Dr. Kinch was a postdoctoral fellow at the University of North Carolina at Chapel Hill, obtained a Ph.D. in Immunology from Duke University and a B.S. in Molecular Genetics from The Ohio State University. He has published more than 100 manuscripts, and been granted 15 US patents. His first book, A Prescription for Change (UNC Press, 2016), outlines a history of the biotechnology and pharmaceutical industries. Michael’s second book, Between Hope and Fear (Pegasus Books, 2018) details the history of vaccines and public reaction to these vital tools. The End of the Beginning (Pegasus Books, 2019) provides a history of new cancer therapies with the potential promise to eradicate this disease. The Price of Health (Simon & Schuster, 2021), investigates the rationale contributing to the rise in drug prices and what might be done about this key problem.